p73 Interacts with Human Immunodeficiency Virus Type 1 Tat in Astrocytic Cells and Prevents Its Acetylation on Lysine 28

REFERENCES

• Alonso, M. E., M. J. Bello, P. Gonzalez-Gomez, J. Lomas, D. Arjona, J. M. de Campos, M. E. Kusak, J. L. Sarasa, A. Isla, and J. A. Rey. 2001. Mutation analysis of the p73 gene in nonastrocytic brain tumours. Br. J. Cancer 85:204–208.
   PubMed Web of Science ®Google Scholar
• Amini, S., A. Clavo, Y. Nadraga, A. Giordano, K. Khalili, and B. E. Sawaya. 2002. Interplay between cdk9 and NF-kappaB factors determines the level of HIV-1 gene transcription in astrocytic cells. Oncogene 21:5797–5803.
   PubMed Web of Science ®Google Scholar
• Ariumi, Y., A. Kaida, M. Hatanaka, and K. Shimotohno. 2001. Functional cross-talk of HIV-1 Tat with p53 through its C-terminal domain. Biochem. Biophys. Res. Commun. 287:556–561.
   PubMedGoogle Scholar
• Bargonetti, J., A. Chicas, D. White, and C. Prives. 1997. p53 represses Sp1 DNA binding and HIV-LTR directed transcription. Cell Mol. Biol. (Noisy-le-grand) 43:935–949.
   PubMedGoogle Scholar
• Bres, V., H. Tagami, J.-M. Peloponese, E. Loret, K. T. Jeang, Y. Nakatani, S. Emiliani, M. Benkirane, and R. Kiernan. 2002. Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and PCAF. EMBO J. 21:6811–6819.
   PubMedGoogle Scholar
• Col, E., C. Caron, D. Seigneurin-Berny, J. Gracia, A. Favier, and S. Khochbin. 2001. The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat. J. Biol. Chem. 276:28179–28184.
   PubMed Web of Science ®Google Scholar
• Deb, D., A. Lanyi, M. Scian, J. Keiger, D. R. Brown, D. Le Roith, S. P. Deb, and S. Deb. 2001. Differential modulation of cellular and viral promoters by p73 and p53. Int. J. Oncol. 18:401–409.
   PubMedGoogle Scholar
• Dorr, A., V. Kiermer, A. Pedal, H. R. Rackwitz, P. Henklein, U. Schubert, M. M. Zhou, E. Verdin, and M. Ott. 2002. Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain. EMBO J. 21:2715–2723.
   PubMed Web of Science ®Google Scholar
• Duan, L., I. Ozaki, J. W. Oakes, J. P. Taylor, K. Khalili, and R. J. Pomerantz. 1994. The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication. J. Virol. 68:4302–4313.
   PubMed Web of Science ®Google Scholar
• Esposito, G., A. Ligresti, A. A. Izzo, T. Bisogno, M. Ruvo, M. Di Rosa, V. Di Marzo, and T. Iuvone. 2002. The endocannabinoid system protects rat glioma cells against HIV-1 Tat protein-induced cytotoxicity. Mechanism and regulation. J. Biol. Chem. 277:50348–50354.
   PubMedGoogle Scholar
• Fulco, M., A. Costanzo, P. Merlo, R. Mangiacasale, S. Strano, G. Blandino, C. Balsano, P. Lavia, and M. Levrero. 2003. p73 is regulated by phosphorylation at the G2/M transition. J. Biol. Chem. 278:49196–49202.
   PubMedGoogle Scholar
• Garden, G. A., W. Guo, S. Jayadev, C. Tun, S. Balcaitis, J. Choi, T. J. Montine, T. Moller, and R. S. Morrison. 2004. HIV associated neurodegeneration requires p53 in neurons and microglia. FASEB J. 18:1141–1143.
   PubMed Web of Science ®Google Scholar
• Gray, F., L. Belec, F. Chretien, M. L. Dubreuil-Lemaire, F. Ricolfi, L. Wingertsmann, F. Poron, and R. Gherardi. 1998. Acute, relapsing brain oedema with diffuse blood-brain barrier alteration and axonal damage in the acquired immunodeficiency syndrome. Neuropathol. Appl. Neurobiol. 24:209–216.
   PubMedGoogle Scholar
• Gualberto, A., and A. S. Baldwin, Jr. 1995. p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. J. Biol. Chem. 270:19680–19683.
   PubMedGoogle Scholar
• Harrod, R., J. Nacsa, C. Van Lint, J. Hansen, T. Karpova, J. McNally, and G. Franchini. 2003. Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription. J. Biol. Chem. 278:12310–12318.
   PubMed Web of Science ®Google Scholar
• Haughey, N. J., R. G. Cutler, A. Tamara, J. C. McArthur, D. L. Vargas, C. A. Pardo, J. Turchan, A. Nath, and M. P. Mattson. 2004. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann. Neurol. 55:257–267.
   PubMed Web of Science ®Google Scholar
• Hottiger, M. O., and G. J. Nabel. 1998. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J. Virol. 72:8252–8256.
   PubMed Web of Science ®Google Scholar
• Jeang, K. T., H. Xiao, and E. A. Rich. 1999. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J. Biol. Chem. 274:28837–28840.
   PubMed Web of Science ®Google Scholar
• Jia, H., M. Lohr, S. Jezequel, D. Davis, S. Shaikh, D. Selwood, and I. Zachary. 2001. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis. Biochem. Biophys. Res. Commun. 283:469–479.
   PubMed Web of Science ®Google Scholar
• Jordan, A., P. Defechereux, and E. Verdin. 2001. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 20:1726–1738.
   PubMed Web of Science ®Google Scholar
• Jost, C. A., C. M. Marin, and W. G. Kaelin, Jr. 1997. p73 is a human p53-related protein that can induce apoptosis. Nature 389:191–194.
   PubMed Web of Science ®Google Scholar
• Kaehlcke, K., A. Dorr, C. Hetzer-Egger, V. Kiermer, P. Henklein, M. Schnoelzer, E. Loret, P. A. Cole, E. Verdin, and M. Ott. 2003. Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation. Mol. Cell 12:167–176.
   PubMed Web of Science ®Google Scholar
• Kaghad, M., H. Bonnet, A. Yang, L. Creancier, J. Biscan, A. Valent, A. Minty, P. Chalon, J. Lelias, X. Dumont, P. Ferrara, F. McKeon, and D. Caput. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809–819.
   PubMed Web of Science ®Google Scholar
• Kiernan, R. E., C. Vanhulle, L. Schiltz, E. Adam, H. Xiao, F. Maudoux, C. Calomme, A. Burny, Y. Nakatani, K. T. Jeang, M. Benkirane, and C. Van Lint. 1999. HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J. 18:6106–6118.
   PubMed Web of Science ®Google Scholar
• Lemasson, I., and J. K. Nyborg. 2001. Human T-cell leukemia virus type I tax repression of p73beta is mediated through competition for the C/H1 domain of CBP. J. Biol. Chem. 276:15720–15727.
   PubMed Web of Science ®Google Scholar
• Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323–331.
   PubMed Web of Science ®Google Scholar
• Levrero, M., V. De Laurenzi, A. Costanzo, J. Gong, G. Melino, and J. Y. Wang. 1999. Structure, function and regulation of p63 and p73. Cell Death Differ. 12:1146–1153.
   Google Scholar
• Li, C. J., C. Wang, D. J. Friedman, and A. B. Pardee. 1995. Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 92:5461–5464.
   PubMed Web of Science ®Google Scholar
• Longo, F., M. A. Marchetti, L. Castagnoli, P. A. Battaglia, and F. Gigliani. 1995. A novel approach to protein-protein interaction: complex formation between the p53 tumor suppressor and the HIV Tat proteins. Biochem. Biophys. Res. Commun. 206:326–334.
   PubMed Web of Science ®Google Scholar
• Minty, A., X. Dumont, M. Kaghad, and D. Caput. 2000. Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J. Biol. Chem. 275:36316–36323.
   PubMed Web of Science ®Google Scholar
• Mujtaba, S., Y. He, L. Zeng, A. Farooq, J. E. Carlson, M. Ott, E. Verdin, and M. M. Zhou. 2002. Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol. Cell 9:575–586.
   PubMed Web of Science ®Google Scholar
• Ogryzko, V. V., R. L. Schiltz, V. Russanova, B. H. Howard, and Y. Nakatani. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953–959.
   PubMed Web of Science ®Google Scholar
• Park, J. S., E. J. Kim, J. Y. Lee, H. S. Sin, S. E. Namkoong, and S. J. Um. 2001. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins. Int. J. Cancer 91:822–827.
   PubMed Web of Science ®Google Scholar
• Pozniak, C. D., S. Radinovic, A. Yang, F. McKeon, D. R. Kaplan, and F. D. Miller. 2000. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289:304–306.
   PubMed Web of Science ®Google Scholar
• Regulier, E. G., K. Reiss, K. Khalili, S. Amini, J. Rappaport, J. F. Zagury, and P. D. Katsikis. 2004. T-cell and neuronal apoptosis in HIV infection: implications for therapeutic intervention. Int. Rev. Immunol. 23:25–59.
   PubMed Web of Science ®Google Scholar
• Sawaya, B. E., K. Khalili, J. Gordon, R. Taube, and S. Amini. 2000. Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J. Biol. Chem. 275:35209–35214.
   PubMed Web of Science ®Google Scholar
• Sawaya, B. E., K. Khalili, W. E. Mercer, L. Denisova, and S. Amini. 1998. Cooperative actions of HIV-1 Vpr and p53 modulate viral gene transcription. J. Biol. Chem. 273:20052–20057.
   PubMed Web of Science ®Google Scholar
• Silva, C., K. Zhang, S. Tsutsui, J. K. Holden, M. J. Gill, and C. Power. 2003. Growth hormone prevents human immunodeficiency virus-induced neuronal p53 expression. Ann. Neurol. 54:605–614.
   PubMedGoogle Scholar
• Sperber, K., and L. Shao. 2003. Neurologic consequences of HIV infection in the era of HAART. AIDS Patient Care STDS 17:509–518.
   PubMed Web of Science ®Google Scholar
• Subler, M. A., D. W. Martin, and S. Deb. 1994. Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. J. Virol. 68:103–110.
   PubMed Web of Science ®Google Scholar
• Thompson, K. A., J. C. McArthur, and S. L. Wesselingh. 2001. Correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia. Ann. Neurol. 49:745–752.
   PubMed Web of Science ®Google Scholar
• Walker, K. K., and A. J. Levine. 1996. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA 93:15335–15340.
   PubMed Web of Science ®Google Scholar
• Wang, Z., G. Trillo-Pazos, S. Y. Kim, M. Canki, S. Morgello, L. R. Sharer, H. A. Gelbard, Z. Z. Su, D. C. Kang, A. I. Brooks, P. B. Fisher, and D. J. Volsky. 2004. Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis. J. Neurovirol. 10(Suppl. 1):25–32.
   PubMedGoogle Scholar
• Watanabe, K., T. Ozaki, T. Nakagawa, K. Miyazaki, M. Takahashi, M. Hosoda, S. Hayashi, S. Todo, and A. Nakagawara. 2002. Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function. J. Biol. Chem. 277:15113–15123.
   PubMedGoogle Scholar
• Weed, M. R., L. H. Gold, I. Polis, G. F. Koob, H. S. Fox, and M. A. Taffe. 2004. Impaired performance on a rhesus monkey neuropsychological testing battery following simian immunodeficiency virus infection. AIDS Res. Hum. Retrovir. 20:77–89.
   PubMedGoogle Scholar
• Wei, P., M. E. Garber, S. M. Fang, W. H. Fischer, and K. A. Jones. 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451–462.
   PubMed Web of Science ®Google Scholar
• Weissman, J. D., J. R. Hwang, and D. S. Singer. 2001. Extensive interactions between HIV TAT and TAF (II)250. Biochim. Biophys. Acta 1546:156–163.
   PubMed Web of Science ®Google Scholar
• Wells, J., and P. J. Farnham. 2002. Characterizing transcription factor binding sites using formaldehyde crosslinking and immunoprecipitation. Methods 26:48–56.
   PubMed Web of Science ®Google Scholar
• Wong, K., A. Sharma, S. Awasthi, E. F. Matlock, L. Rogers, C. Van Lint, D. J. Skiest, D. K. Burns, and R. Harrod. 2005. HIV-1 Tat interactions with p300 and PCAF transcriptional coactivators inhibit histone acetylation and neurotrophin-signaling through CREB. J. Biol. Chem. 280:9390–9399.
   PubMed Web of Science ®Google Scholar
• Wright, C. M., B. K. Felber, H. Paskalis, and G. N. Pavlakis. 1986. Expression and characterization of the trans-activator HTLV-III/LAV virus. Science 234:988–992.
   PubMedGoogle Scholar
• Yang, Y., I. Tikhonov, T. J. Ruckwardt, M. Djavani, J. C. Zapata, C. D. Pauza, and M. S. Salvato. 2003. Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4+ cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J. Virol. 77:6700–6708.
   PubMed Web of Science ®Google Scholar
• Yik, J. H., R. Chen, A. C. Pezda, C. S. Samford, and Q. Zhou. 2004. A human immunodeficiency virus type 1 Tat-like arginine-rich RNA-binding domain is essential for HEXIM1 to inhibit RNA polymerase II transcription through 7SK snRNA-mediated inactivation of P-TEFb. Mol. Cell. Biol. 24:5094–5105.
   PubMed Web of Science ®Google Scholar
• Zauli, G., D. Gibellini, A. Caputo, A. Bassini, M. Negrini, M. Monne, M. Mazzoni, and S. Capitani. 1995. The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood 86:3823–3834.
   PubMed Web of Science ®Google Scholar
• Zeng, X., X. Li, A. Miller, Z. Yuan, W. Yuan, R. P. Kwok, R. Goodman, and H. Lu. 2000. The N-terminal domain of p73 interacts with the CH1 domain of p300/CREB binding protein and mediates transcriptional activation and apoptosis. Mol. Cell. Biol. 20:1299–1310.
   PubMedGoogle Scholar
• Zhou, M., L. Deng, F. Kashanchi, J. N. Brady, A. J. Shatkin, and A. Kumar. 2003. The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA. Proc. Natl. Acad. Sci. USA 100:12666–12671.
   PubMedGoogle Scholar